デフェラシロクス (JAN);
Deferasirox (JAN/USAN/INN)

EXJADE (Novartis Pharmaceuticals Corporation), JADENU (Novartis Pharmaceuticals Corporation)

DEFERASIROX (Actavis Pharma), DEFERASIROX (Actavis Pharma), DEFERASIROX (Alembic Pharmaceuticals), DEFERASIROX (Alembic Pharmaceuticals), DEFERASIROX (Alembic Pharmaceuticals Limited), DEFERASIROX (Alembic Pharmaceuticals Limited), DEFERASIROX (Amneal Pharmaceuticals NY LLC), DEFERASIROX (Ascend Laboratories), DEFERASIROX (Ascend Laboratories), DEFERASIROX (Bionpharma), DEFERASIROX (Cadila Healthcare Limited), DEFERASIROX (Cipla USA), DEFERASIROX (Dr. Reddy's Laboratories), DEFERASIROX (Dr. Reddy's Laboratories), DEFERASIROX (Glenmark Pharmaceuticals), DEFERASIROX (MSN LABORATORIES PRIVATE LIMITED), DEFERASIROX (MSN LABORATORIES PRIVATE LIMITED), DEFERASIROX (Northstar Rx LLC.), DEFERASIROX (Sun Pharmaceutical Industries), DEFERASIROX (Sun Pharmaceutical Industries), DEFERASIROX (Teva Pharmaceuticals USA), DEFERASIROX (Xiromed), DEFERASIROX (Zydus Pharmaceuticals (USA)), DEFERASIROX ORAL (Ascend Laboratories)

C21H15N3O4

373.1063

373.3615

解毒薬 (鉄過剰蓄積), キレート剤

Enzyme: UGT1A1 [HSA:54658], UGT1A3 [HSA:54659]

CYP inhibition: CYP1A2 [HSA:1544], CYP2C8 [HSA:1558]
CYP induction: CYP3A4 [HSA:1576]
DDI search